ASH 2014: Takeda's oral ixazomib succeeds as myeloma maintenance therapy
This article was originally published in Scrip
Executive Summary
Ixazomib (MLN9708), Takeda Oncology's oral follow-on to Velcade (bortezomib), showed in a Phase II clinical trial that the proteasome inhibitor could offer safety and convenience for previously untreated multiple myeloma patients who are in the maintenance phase of treatment.